Association of serum vitamin d level with diabetic polyneuropathy in rural population of central India

Manoj Kumar; Sushil Kumar; Shailja Katiyar; Pankaj Kumar

doi:10.53730/ijhs.v6nS3.5612

Authors

Manoj Kumar Professor & Head of Department, Medicine, UPUMS, SAIFAI, ETAWAH, Uttar Pradesh
Sushil Kumar Assistant Professor, Medicine Department UPUMS, Saifai, ETAWAH, Uttar Pradesh
Shailja Katiyar Senior Resident, Department of OBS & Gynae, UPUMS, SAIFAI, ETAWAH, Uttar Pradesh
Pankaj Kumar Assistant Professor, Medicine Department UPUMS, Saifai, ETAWAH, Uttar Pradesh

Keywords:

serum vitamin D, diabetic polyneuropathy, neuropathy, 25-hydroxyvitamin D

Abstract

To evaluate association of serum Vitamin D level and development of polyneuropathy. This was a case -control study and the study was conducted on an outpatient basis. Fifty-five subjects were recruited from the Medicine OPD of UPUMS Saifai. All subjects had type-2 diabetes (male and female, 40-60 years old). The Michigan Neuropathy Screening Instrument (15-point questionnaire) was used to identify patients with neuropathy (score > 7/15). 20 patients did not have neuropathy and were designated the control group. 35 patients did have neuropathy (“study group”) and these patients underwent a detailed quantitative neuropathy evaluation by a neurologist using the 46-point Michigan Diabetic Neuropathy Scale (MDNS) and nerve conduction studies. We measured the serum 25-hydroxyvitamin D concentrations with liquid chromatography-tandem mass spectrometry (LC/MS) chromatography in all patients. These values were compared between the control and study group, and were correlated with the detailed neuropathy score in the study group. Patients with diabetic polyneuropathy had a lower mean serum 25- hydroxyvitamin D level (16. 41 ng/ml with the SD of: 2.026) in comparison to the controls (38.76 ng/ml with the SD of 5.483).

Downloads

Download data is not yet available.

References

Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am. 1998 Jul. 82(4):909-29.

Goetz CG, Pappert EJ. Textbook of Clinical Neurology. Philadelphia: WB Saunders Co; 1999.

Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy--a continuing enigma. Diabetes Metab Res Rev. 2000 Nov-Dec. 16(6):408-33.

Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M. Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care. 1997 Dec. 20(12):1896-9.

Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. 2010 Mar 30.

Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M. Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care. 1997 Dec. 20(12):1896-9.

Carrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th century. Diabetes Reviews. 1999. 7:275-99.

Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology. 1999 Aug 11. 53(3):580-91.

Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci. 1995 Mar. 129(1):62-8

Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008 Dec. 9(4):301-14.

Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 1998 Sep. 51(3):695-702.

Krendel DA, Zacharias A, Younger DS. Autoimmune diabetic neuropathy. Neurol Clin. 1997 Nov. 15(4):959-71.

Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep 30. 329(14):977-86.

Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999. 107(7):421-30.

Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA (1994). A practical two-step, Quantitative Clinical And Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes care. 17(11): 1281-9.

Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK (2006). HPLC Method for 25- Hydroxyvitamin D Measurement: Comparison with Contemporary Assays. Clin. Chem., 52:61120-1126.

Mattila C, Kenkt P, Mannisto S, Rissanen H, Laaksonen MA, Montonen J, Reunanen J (2007). Serum 25- Hydroxyvitamin D Concentration and Subsequent Risk of type 2 Diabetes. Diabetes Care, 30(10):2569-2570.

Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007).The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta- Analysis. J. Clin. Endocrinol. Metab., 92(6): 2017-2029.

Chabas JF, Alluin O, Rao G, Garcia S, Lavaut MN, Risso JJ, Lagre R, Magalon G, Khrestchatsky M, Marqueste T, Decherchi P, Feron F (2008). Vitamin D2 potentiates axon regeneration, J. Neurotrauma,25 (10): 1247-1256.

Garcion E, Wion-Barbot P, Montero-Menei CN, Berger F, Didier W (2002). New clues about vitamin D functions in the nervous system, Trends in Endocrinology and Metabolism, pp.1043-2760.

Fukuoka M, Sakurai K, Ohta T, Kioki M, Katayama L (2001), Tacalcitol, an Active Vitamin D3, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes. Skin Pharmacol. Appl. Skin Physiol., 14(4): 226-233.

Lee P, Chen R (2008), Vitamin D as an analgesic for patients with type-2 diabetes and neuropathic pain, Arch. Int. Med., 168(7): 771-772.